Katherine Geiersbach, M.D., explains how Mayo Clinic Laboratories' PIK3CA assay informs breast cancer treatment. The assay identifies patients eligible for a certain second-line therapy when initial treatment has failed.
A research team led by Fergus Couch, Ph.D., a geneticist at Mayo Clinic, has identified specific genes associated with an increased risk for developing triple-negative breast cancer. The team's research was published in the Journal of the National Cancer Institute.
In this month’s “Hot Topic,” my colleagues, Dr. Katherine Geiersbach and Dr. Beiyun Chen, will provide information about the 2018 Focused Update of the ASCO/CAP guidelines for HER2 testing in breast cancer.
This week’s Research Roundup highlights a model for predicting breast cancer risk in women with atypical hyperplasia.
A new test developed by researchers at Mayo Clinic shows which mutations in the BRCA2 gene make women susceptible to developing breast or ovarian cancers. The research behind the test was published today in the American Journal of Human Genetics.
This week’s Research Roundup highlights the evaluation of polygenic risk scores for breast and ovarian cancer risk prediction in BRCA1 and BRCA2 mutation carriers.